Century Therapeutics Q3 EPS $(0.55) Misses $(0.51) Estimate, Sales $148.00K Miss $1.16M Estimate
Portfolio Pulse from Benzinga Newsdesk
Century Therapeutics (NASDAQ:IPSC) reported Q3 losses of $(0.55) per share, missing the analyst consensus estimate of $(0.51) by 7.84%. The company also reported quarterly sales of $148.00K, missing the analyst consensus estimate of $1.16M by 87.24%. This represents a decrease in both earnings and sales compared to the same period last year.
November 09, 2023 | 12:46 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Century Therapeutics' Q3 earnings and sales missed analyst estimates, indicating a potential negative impact on the company's stock.
Century Therapeutics reported lower than expected earnings and sales for Q3. This underperformance could negatively impact investor sentiment and lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100